Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXPNYSE / NASDAQHealthcareSmall cap

$2.38-$0.17 (-6.7%)

Last close · Data as of Nov 20, 2026

Market cap
$189.4M
P/E
-1.5x
EV / EBITDA
0.1x
Revenue
$13.1M
Net margin
-946.2%
ROCE
-49.8%

-84.8% over the last year

Tonix Pharmaceuticals Holding Corp. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-58.8%
3M
-80.8%
6M
-83.6%
1Y
-84.8%
5Y
Hidden
  • This period includes a one-day price step on 3 Feb 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.17 (-6.7%) from $3 to $2 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TNXP, bought on each weekday since 2021.

News & filings

What Tonix Pharmaceuticals Holding filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 124 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.42 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Read moreShow less

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Sector
Healthcare
Shares outstanding
12.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$189.4M
P/E
-1.5x
P/B
0.8x
EV / EBITDA
0.1x
EV / Sales
-1.3x
P/S
14.4x
52-week high
$19.89
52-week low
$2.38

Profitability

Operating margin
-936.1%
Net margin
-946.2%
EBITDA margin
-930.9%
ROE
-50.6%
ROCE
-49.8%
ROIC
-252.2%
ROA
-44.7%
Asset turnover
0.05

Growth

Revenue
$13.1M
Revenue growth, 1Y
29.8%
Net profit growth, 1Y
-4.6%
Free cash flow
-$103.2M

Solvency

Current ratio
7.42
Debt / Equity
0.01
Debt / Assets
0.00
CFO / Net profit
0.81
Cash / Market cap
109.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$13.1M
Cost of revenue$6.6M
Gross profit$6.5M
Operating expenses$129.2M
Research and development$44.5M
Selling, general and administrative$87.7M
Operating income-$122.7M
Interest and other-$1.3M
Pretax income-$124.0M
Tax and other$0.00
Net income-$124.0M

Revenue and net profit

Revenue grew 29.8% in FY2025; net profit is the dashed line.

Tonix Pharmaceuticals Holding Corp. revenue and net profit by fiscal year
Tonix Pharmaceuticals Holding Corp. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$110.2M
FY2023$7.8M-$116.7M
FY2024$10.1M-$130.0M
FY2025$13.1M-$124.0M

Cash flows

FY2025: -$99.8M from operations, -$103.2M free after investment (dashed).

Tonix Pharmaceuticals Holding Corp. operating and free cash flow by fiscal year
Tonix Pharmaceuticals Holding Corp. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$98.1M-$146.2M
FY2023-$102.0M-$109.9M
FY2024-$60.9M-$61.0M
FY2025-$99.8M-$103.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$13.1M+29.8%1Y
EBITDA
-$122.0M
Net profit
-$124.0M
Cash from operations
-$99.8M
Free cash flow
-$103.2M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$13.1M-$122.0M-$124.0M-$103.2M-50.6%+29.8%-4.6%

Monthly returns

Month-by-month returns of TNXP across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$277.2M
Liabilities$32.0M
Equity$245.2M
Paid-in capital$1.1B
Retained earnings-$854.7M

Market cap against peers

8 peers: same sector, nearest by size.

  1. Tonix Pharmaceuticals Holding Corp. (this company)$189.4M

Peers map

Healthcare companies placed by value, growth and quality; TNXP highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Tonix Pharmaceuticals Holding Corp. (this company)-1.3x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Tonix Pharmaceuticals Holding Corp.TNXPthis company$189.4M-1.5x0.8x-50.6%0.1x
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Cartesian Therapeutics, Inc.RNAC$192.4M-1.5x-1.5x103.2%-1.0x
KORU Medical Systems, Inc.KRMD$190.2M-72.1x11.2x-15.5%-85.5x
MediWound Ltd.MDWD$185.7M-7.8x4.3x-54.7%-8.8x
Stereotaxis, Inc.STXS$183.7M-8.5x13.6x-160.5%-8.5x
Quanterix CorporationQTRX$179.0M-1.7x0.6x-36.2%-2.1x
Peer median—-8.1x2.8x-34.8%-8.7x

Year-to-date ROI

TNXP since 1 January, against earlier years.

Historical volatility

TNXP's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Tonix Pharmaceuticals Holding Corp. operating margin by fiscal year
Tonix Pharmaceuticals Holding Corp. operating margin by fiscal year
DateOperating margin
FY2023-1523.6%
FY2024-744.8%
FY2025-935.9%
LineFY2025
Cost of revenueCost Of Revenue$6.6M
Gross profitGross Profit$6.5M
Operating expensesOperating Expense$129.2M
Research and developmentResearch And Development$44.5M
Other operating expensesOther Operating Expenses-$3.0M
Total expensesTotal Expenses$135.8M
Pretax incomePretax Income-$124.0M

Learn while you research

Academy chapters picked for Tonix Pharmaceuticals Holding Corp. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing30% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →